ArticleThe Journal of clinical investigation2022

SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers.

Zhen Lu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.